Athersys Revenue and Competitors
Estimated Revenue & Valuation
- Athersys's estimated annual revenue is currently $35M per year.
- Athersys's estimated revenue per employee is $614,035
- Athersys's total funding is $122.7M.
Employee Data
- Athersys has 57 Employees.
- Athersys grew their employee count by -37% last year.
Athersys's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Interim CFO | Reveal Email/Phone |
3 | SVP Finance | Reveal Email/Phone |
4 | VP, Regenerative Medicine, Head Business Development | Reveal Email/Phone |
5 | VP Operations | Reveal Email/Phone |
6 | VP, Technical Operations | Reveal Email/Phone |
7 | SVP Commercial Manufacturing | Reveal Email/Phone |
8 | VP and Head Information Technology and Communications | Reveal Email/Phone |
9 | VP Finance | Reveal Email/Phone |
10 | EVP, Head Global Regulatory Affairs | Reveal Email/Phone |
Athersys Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $1.7M | 11 | 0% | N/A | N/A |
#3 | $0.8M | 5 | 0% | N/A | N/A |
#4 | $5.1M | 33 | 14% | N/A | N/A |
#5 | $64.6M | 417 | 2% | N/A | N/A |
#6 | $1.7M | 11 | -8% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $7.4M | 48 | -41% | N/A | N/A |
#9 | $0.6M | 4 | 0% | N/A | N/A |
#10 | $0.9M | 12 | 20% | N/A | N/A |
What Is Athersys?
Athersys is a functional genomics and biopharmaceutical company engaged in the development, application and commercialization of novel gene expression tools and therapeutic products. The company’s research and development programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expression™) and SMC™ (Synthetic Microchromosome™) vector system.
keywords:Biotechnology
$122.7M
Total Funding
57
Number of Employees
$35M
Revenue (est)
-37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Athersys News
Athersys Inc., the biotechnology company in Cleveland, could be nearing the end of a 15-year journey to commercialize its adult stem cell...
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance...
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance...
Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 study it’s conducting with Pfizer. The randomized, double-blind, placebo-controlled study has enrolled 88 ulcerative colitis patients in the U.S., Canada and Europe who have had the disease for an average ...
Already the company has two Phase 2 trials in progress, although one has been held up by enrollment challenges. Athersys is working with Pfizer on a trial of MultiStem in treatment-resistant ulcerative colitis patients. Last time we checked in with the company, enrollment for the study had been ...
Other Companies in Cleveland
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 57 | 0% | N/A |
#2 | $3.5M | 57 | 43% | N/A |
#3 | $10.5M | 57 | 0% | N/A |
#4 | N/A | 57 | 30% | N/A |
#5 | $13.9M | 57 | 10% | N/A |